Navigation Links
Data Available From Erbitux Phase III Study in First-Line Treatment,of Advanced Lung Cancer

ective response rates. Currently, no data are available that demonstrate an improvement in disease-related symptoms or increased survival with ERBITUX for the treatment of EGFR-expressing mCRC.

For full prescribing information, including boxed WARNINGS regarding infusion reactions and cardiopulmonary arrest, visit http://www.ERBITUX.com.

Important Safety Information

Grade 3/4 infusion reactions, rarely with fatal outcome (<1 in 1000), occurred in approximately 3% (46/1485) of patients receiving ERBITUX (Cetuximab) therapy. These reactions are characterized by rapid onset of airway obstruction (bronchospasm, stridor, hoarseness), urticaria, hypotension, loss of consciousness, and/or cardiac arrest. Severe infusion reactions require immediate and permanent discontinuation of ERBITUX therapy.

Most reactions (90%) were associated with the first infusion of ERBITUX despite the use of prophylactic antihistamines. Caution must be exercised with every ERBITUX infusion as there were patients who experienced their first severe infusion reaction during later infusions. A 1-hour observation period is recommended following the ERBITUX infusion. Longer observation periods may be required in patients who experience infusion reactions.

Cardiopulmonary arrest and/or sudden death occurred in 2% (4/208) of patients with squamous cell carcinoma of the head and neck treated with radiation therapy and ERBITUX as compared to none of 212 patients treated with radiation therapy alone. Fatal events occurred within 1 to 43 days after the last ERBITUX treatment. ERBITUX in combination with radiation therapy should be used with caution in patients with known coronary artery disease, congestive heart failure and arrhythmias. Close monitoring of serum electrolytes, including serum magnesium, potassium, and calcium during and after ERBITUX therapy is recommended.

Severe cases of interstitial lung disea
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
2. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
3. Data Available from Erbitux Phase III Study in First-Line Treatment of Advanced Pancreatic Cancer
4. Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
5. Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
6. Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
7. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
8. Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:8/19/2014)... COLUMBUS, Ohio , Aug. 19, 2014 ... Ohio medical device company, announced today that ... FloShield laparoscopic and robotic visualization system in ... approved for sale in Japan ... Corporation is also the exclusive distributor for Karl Storz ...
(Date:8/19/2014)... DUBLIN , Aug. 19, 2014 Research ... "Human Growth Hormone Drugs - Global Strategic Business Report" ... the worldwide markets for Human Growth Hormone Drugs in US$ ... and Others. The report provides separate comprehensive analytics ... Japan , Europe , ...
(Date:8/19/2014)... -- According to Kalorama Information, electronic medical records (EMR) ... in healthcare a reality, and this a factor that ... Recovery and Reinvestment Act, the U.S. government dedicated $20.6 ... will start applying soon for use of paper records.  ... of the EMR industry, EMR 2014: The Market ...
Breaking Medicine Technology:Minimally Invasive Devices and Mitsubishi Medical Japan Forge Exclusive Distribution Agreement 2Global Human Growth Hormone Drugs - Strategic Business Report 2014 2Kalorama: EMR Paves the Way for Big Data 2Kalorama: EMR Paves the Way for Big Data 3
... ANGELES, Jan. 13, 2011 UBM Canon and ... webinar to its webcast series on The Fundamentals of ... on Advanced Assay Technologies and Development Methods ... experts in the industry.   (Logo:   ...
... 13, 2011 CareGiver remote instrument support has expanded ... Medical System, Inc. ("VMSI") is the leading innovator in ... 5 years of success on the SYMPHONY H&E slide ... BenchMark ULTRA, strengthening the integration of the SYMPHONY and ...
Cached Medicine Technology:Advanced Assay Technologies and Development Methods 2CareGiver, Ventana Medical Systems, Inc. Remote Instrument Support, Has Expanded to Include the Ventana BenchMark ULTRA Automated Stainer 2CareGiver, Ventana Medical Systems, Inc. Remote Instrument Support, Has Expanded to Include the Ventana BenchMark ULTRA Automated Stainer 3
(Date:8/20/2014)... August 20, 2014 It’s no secret ... According to the National Institute on Drug Abuse, nearly ... drugs. What’s even more alarming is the fact that ... last decade. , Those locked in a struggle with ... way out. But now, the newly-redesigned AbuseTreatmentCenters.net has released ...
(Date:8/20/2014)... 20, 2014 One Call Alert expands its ... of ResCube, a fully-mobile wearable device that connects customers to ... button, 24 hours a day, 365 days a year. , ... cross country. It operates on the T-Mobile nationwide network like ... in to work. , Like with the other One Call ...
(Date:8/20/2014)... at the Universities of Manchester and Auckland suggest that both ... mechanism. , The findings, published today in the ... or type-1 diabetes and type-2 diabetes are both caused by ... , The results, based on 20 years, work ... both be slowed down and potentially reversed by medicines that ...
(Date:8/20/2014)... Fresh from the cradle of a world-class running city, an ... , Urbini, a new collection of versatile baby gear from ... jogger to its lineup. , The Avi has been in ... the latest racing styles and a set of features to ... a swift, smooth ride on runs, power-walks and causal strolls. ...
(Date:8/20/2014)... 20, 2014 Today, Zane Benefits, the ... open enrollment for 2015. , According to Zane Benefits, ... in November, employees are encouraged to start thinking about ... 2015, the open enrollment period will run from November ... 2015 individuals can purchase a new individual health insurance ...
Breaking Medicine News(10 mins):Health News:Re-Launched AbuseTreatmentCenters.net Offering New List of Substance Abuse Resources 2Health News:One Call Alert Introduces ResCube™, Smallest Mobile Medical Alert System on Market 2Health News:One Call Alert Introduces ResCube™, Smallest Mobile Medical Alert System on Market 3Health News:Scientists show type-1 and type-2 diabetes are caused by same underlying mechanism 2Health News:Urbini Breezes Through Summer with New Jogging Stroller 2
... , , WESTBURY, N.Y., July ... in the Ophthalmic Consultants of Long Island (OCLI) practice will perform ... of sight to those who have lost some or all of ... Cataract USA program, is offering this outpatient surgical procedure to residents ...
... , , , HOUSTON, ... , , If you would like to learn ... Texas Health Institute as they host a morning-long forum on "Building a Federal ... The event will be held at St. Joseph Medical Center, 1401 St. ...
... NxStage Medical, Inc. (Nasdaq: NXTM ), a leading ... financial results for the second quarter ended June 30, 2009 on ... , , NxStage will also host ... 5, 2009 to discuss its second quarter financial results. To listen ...
... , , WALTHAM, Mass., ... and advisory firms focusing on pharmaceutical and healthcare issues, finds that ... million in 2008 to more than $315 million in 2013. The ... Humira and Schering-Plough,s Remicade which recorded sales of $50 million and ...
... , , BANNOCKBURN, Ill., July ... in the United States(1). Yet it,s often not until the untimely passing ... or Tim Russert - that the issue is brought to the forefront ... heightened focus on heart health, a recent survey(2) uncovered that only 14 ...
... on intelligence tests at age 5 , MONDAY, July ... of a common airborne pollutant compound seems to threaten ... , The finding is based on the experience of ... City area. Specifically, it indicates that high prenatal exposure ...
Cached Medicine News:Health News:Ophthalmic Consultants of Long Island (OCLI), the Largest and One of the Most Prestigious Multi-Specialty Ophthalmology Practices on Long Island, Participates in Mission Cataract USA 2Health News:Ophthalmic Consultants of Long Island (OCLI), the Largest and One of the Most Prestigious Multi-Specialty Ophthalmology Practices on Long Island, Participates in Mission Cataract USA 3Health News:Building a Federal Health Board - Impact on Texas 2Health News:NxStage to Report Second Quarter 2009 Financial Results 2Health News:Brazil's Rheumatoid Arthritis Drug Market Will Grow $115 Million by 2013 2Health News:Need for At-Home Blood Pressure Monitoring Underscored by High-Profile Cardiac Deaths 2Health News:Need for At-Home Blood Pressure Monitoring Underscored by High-Profile Cardiac Deaths 3Health News:Exposure to Common Pollutant in Womb Might Lower IQ 2Health News:Exposure to Common Pollutant in Womb Might Lower IQ 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: